OncoMatch/Clinical Trials/NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Is NCT05201781 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Cilta-cel for multiple myeloma.
Treatment: Cilta-cel — The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: CAR-T cell therapy (ciltacabtagene autoleucel) — Company-sponsored clinical study
Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Cancer Center-Scottsdale · Phoenix, Arizona
- City of Hope · Duarte, California
- University of California San Francisco · San Francisco, California
- Stanford University Medical Center · Stanford, California
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify